Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay A Berzofsky

Showing results (1-10 of 199) with videos related to

Pageof 20
Sort By:
Vaccine|November 26, 2011
A push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responsesJay A Berzofsky
Science Translational Medicine|February 11, 2012
Improving immunotherapy: revisiting the immunologist's little secretJay A Berzofsky
Immunity|December 15, 2021
Thomas Alexander WaldmannJay A Berzofsky
Current Opinion in Immunology|March 17, 2004
Immunoregulatory T cells in tumor immunityMasaki Terabe, Jay A Berzofsky
Advances in Cancer Research|December 6, 2008
The role of NKT cells in tumor immunityMasaki Terabe, Jay A Berzofsky
Trends in Immunology|October 30, 2007
NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axisMasaki Terabe, Jay A Berzofsky
Gut Microbes|March 16, 2013
Oral vaccines: directed safe passage to the front line of defenseQing Zhu, Jay A Berzofsky
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2008
NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axisJay A Berzofsky, Masaki Terabe
Current Molecular Medicine|August 20, 2009
The contrasting roles of NKT cells in tumor immunityJay A Berzofsky, Masaki Terabe
Cancer Immunology, Immunotherapy : CII|January 4, 2014
The immunoregulatory role of type I and type II NKT cells in cancer and other diseasesMasaki Terabe, Jay A Berzofsky
Pageof 20

Showing results (1-10 of 199) with videos related to

Sort By:
Pageof 20
Vaccine|November 26, 2011
A push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responsesJay A Berzofsky
Science Translational Medicine|February 11, 2012
Improving immunotherapy: revisiting the immunologist's little secretJay A Berzofsky
Immunity|December 15, 2021
Thomas Alexander WaldmannJay A Berzofsky
Current Opinion in Immunology|March 17, 2004
Immunoregulatory T cells in tumor immunityMasaki Terabe, Jay A Berzofsky
Advances in Cancer Research|December 6, 2008
The role of NKT cells in tumor immunityMasaki Terabe, Jay A Berzofsky
Trends in Immunology|October 30, 2007
NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axisMasaki Terabe, Jay A Berzofsky
Gut Microbes|March 16, 2013
Oral vaccines: directed safe passage to the front line of defenseQing Zhu, Jay A Berzofsky
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2008
NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axisJay A Berzofsky, Masaki Terabe
Current Molecular Medicine|August 20, 2009
The contrasting roles of NKT cells in tumor immunityJay A Berzofsky, Masaki Terabe
Cancer Immunology, Immunotherapy : CII|January 4, 2014
The immunoregulatory role of type I and type II NKT cells in cancer and other diseasesMasaki Terabe, Jay A Berzofsky
Pageof 20